Potential Alzheimer’s therapy

The University of Arizona Center for Innovation in Brain Science has received a $37.5 million grant from the National Institutes of Health to research a potential regenerative therapy for Alzheimer’s disease. The five-year grant will fund a national clinical trial to determine whether alloprognanalone, or allo, is an effective treatment for those with early-stage Alzheimer’s who have a genetic risk for the disease. We hear more from Roberta Diaz Brinton, director of the Center for Innovation in Brain Science.